69 related articles for article (PubMed ID: 9531056)
1. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix.
Hoover-Plow J; Khaitan A; Fless GM
Thromb Haemost; 1998 Mar; 79(3):640-8. PubMed ID: 9531056
[TBL] [Abstract][Full Text] [Related]
2. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix.
Pillarisetti S; Paka L; Obunike JC; Berglund L; Goldberg IJ
J Clin Invest; 1997 Aug; 100(4):867-74. PubMed ID: 9259586
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein lipase greatly enhances the retention of lipoprotein(a) to endothelial cell-matrix.
Auerbach BJ; Cain W; Ansong M; Newton RS; Saxena U; Bisgaier CL
Atherosclerosis; 1999 Jan; 142(1):89-96. PubMed ID: 9920509
[TBL] [Abstract][Full Text] [Related]
4. Enzymatic and chemical modifications of lipoprotein(a) selectively alter its lysine-binding functions.
Hoover-Plow J; Skocir P
Biochim Biophys Acta; 1998 May; 1392(1):73-84. PubMed ID: 9593830
[TBL] [Abstract][Full Text] [Related]
5. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator.
Pekelharing HL; Kleinveld HA; Duif PF; Bouma BN; van Rijn HJ
Thromb Haemost; 1996 Mar; 75(3):497-502. PubMed ID: 8701415
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes.
Yang M; Chu EM; Caslake MJ; Edelstein C; Scanu AM; Hill JS
Biochim Biophys Acta; 2010 Feb; 1801(2):176-82. PubMed ID: 19895904
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix.
Saxena U; Klein MG; Vanni TM; Goldberg IJ
J Clin Invest; 1992 Feb; 89(2):373-80. PubMed ID: 1737833
[TBL] [Abstract][Full Text] [Related]
9. Active site competition is the mechanism for the inhibition of lipoprotein-associated phospholipase A
Zhuo S; Yuan C
Sci Rep; 2020 Oct; 10(1):17232. PubMed ID: 33057060
[TBL] [Abstract][Full Text] [Related]
10. Effect of phospholipase A2 digestion on the conformation and lysine/fibrinogen binding properties of human lipoprotein[a].
Fless GM; Kirk EW; Klezovitch O; Santiago JY; Edelstein C; Hoover-Plow J; Scanu AM
J Lipid Res; 1999 Apr; 40(4):583-92. PubMed ID: 10191282
[TBL] [Abstract][Full Text] [Related]
11. Modification of lipoprotein(a) by oxidation or desialylation influences its ability to compete with plasminogen for binding to the extracellular matrix.
Pekelharing HL; Kleinveld HA; Duif PF; Bouma BN; van Rijn HJ
Blood Coagul Fibrinolysis; 1996 Sep; 7(6):641-9. PubMed ID: 8899154
[TBL] [Abstract][Full Text] [Related]
12. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix.
Marathe S; Kuriakose G; Williams KJ; Tabas I
Arterioscler Thromb Vasc Biol; 1999 Nov; 19(11):2648-58. PubMed ID: 10559007
[TBL] [Abstract][Full Text] [Related]
13. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans.
Oörni K; Hakala JK; Annila A; Ala-Korpela M; Kovanen PT
J Biol Chem; 1998 Oct; 273(44):29127-34. PubMed ID: 9786921
[TBL] [Abstract][Full Text] [Related]
14. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
15. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix.
Lundstam U; Hurt-Camejo E; Olsson G; Sartipy P; Camejo G; Wiklund O
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1162-7. PubMed ID: 10323765
[TBL] [Abstract][Full Text] [Related]
16. Transfer of phospholipase A-resistant pyrene-dialkyl-glycerophosphocholine to plasma lipoproteins: differences between Lp[a] and LDL.
Gorges R; Hofer G; Sommer A; Stütz H; Grillhofer H; Kostner GM; Paltauf F; Hermetter A
J Lipid Res; 1995 Feb; 36(2):251-9. PubMed ID: 7751812
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification.
Sparrow CP; Parthasarathy S; Steinberg D
J Lipid Res; 1988 Jun; 29(6):745-53. PubMed ID: 3139813
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
MacPhee CH; Moores KE; Boyd HF; Dhanak D; Ife RJ; Leach CA; Leake DS; Milliner KJ; Patterson RA; Suckling KE; Tew DG; Hickey DM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):479-87. PubMed ID: 10024526
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro.
Turunen P; Jalkanen J; Heikura T; Puhakka H; Karppi J; Nyyssönen K; Ylä-Herttuala S
J Lipid Res; 2004 Sep; 45(9):1633-9. PubMed ID: 15231855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
